Skip to main content
Signal8
Launch Terminal

ACADIA PHARMACEUTICALS INC (ACAD)

Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

ACADIA Pharmaceuticals Inc. logo

ACADIA Pharmaceuticals Inc.

NASDAQ:ACADHealthcare
-0.82%$20.59
AH$20.59+0.00%vs close
Mkt Cap$3.55B
Float127.68M
O/S172.31M
Vol
$ Vol
RVOL
Inst Own73.4%
SI7.1%
Earnings
Dilution
ACADIA Pharmaceuticals Inc. logoNASDAQ:ACAD$20.59-0.82%
Upcoming Catalysts
Phase Distribution
41 lead-sponsored trials·5 active·25 completed
Phase 215
Phase 2/34
Phase 319
Phase 41
Not applicable2
(9 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Recent Deals
  • Department of Health – Abu DhabiCOLLAB
    Oct 21, 2026
    NEO100NEO212
Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Completed

    Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

    Pimavanserin

    Parkinson Disease Psychosis

    Enrollment
    29
    Start
    Feb 2020
    Primary Completion
    Apr 2022
    Completion
    Apr 2022
    NCT04292223
  • Phase 3
    Completed

    A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

    Pimavanserin tartrate (ACP-103), Pimavanserin tartrate (ACP-103)

    Parkinson's Disease Psychosis

    Enrollment
    298
    Start
    Jun 2007
    Primary Completion
    Jun 2009
    Completion
    Jul 2009
    NCT00477672
  • Phase 3
    Completed

    A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

    Pimavanserin tartrate (ACP-103)

    Parkinson's Disease Psychosis

    Enrollment
    459
    Start
    Jul 2007
    Primary Completion
    May 2018
    Completion
    May 2018
    NCT00550238
  • Phase 3
    Completed

    A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

    Pimavanserin tartrate (ACP-103), Pimavanserin tartrate (ACP-103)

    Parkinson's Disease Psychosis

    Enrollment
    123
    Start
    Mar 2008
    Primary Completion
    Dec 2009
    Completion
    Dec 2009
    NCT00658567
  • Phase 3
    Completed

    A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

    pimavanserin tartrate, placebo

    Parkinson's Disease Psychosis

    Enrollment
    199
    Start
    Jul 2010
    Primary Completion
    Nov 2012
    Completion
    Nov 2012
    NCT01174004
  • Phase 3
    Completed

    Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)

    Pimavanserin, Placebo

    Schizophrenia

    Enrollment
    396
    Start
    Oct 2016
    Primary Completion
    May 2019
    Completion
    Jun 2019
    NCT02970292
  • Phase 3
    Terminated

    Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

    Pimavanserin

    Schizophrenia

    Enrollment
    995
    Start
    Jan 2017
    Primary Completion
    Apr 2024
    Completion
    May 2024
    NCT03121586
  • Phase 3
    Completed

    Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

    Placebo, Pimavanserin 34 mg

    Dementia-related Psychosis

    Enrollment
    392
    Start
    Sep 2017
    Primary Completion
    Jul 2019
    Completion
    Oct 2019
    NCT03325556
  • Phase 3
    Completed

    A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

    Pimavanserin, Placebo

    Neuropsychiatric Symptoms Related to Neurodegenerative Disease

    Enrollment
    784
    Start
    May 2018
    Primary Completion
    May 2022
    Completion
    May 2022
    NCT03575052
  • Phase 3
    Completed

    Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

    Pimavanserin

    Neuropsychiatric Symptoms Related to Neurodegenerative Disease

    Enrollment
    595
    Start
    Jul 2018
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT03623321
  • Phase 3
    Completed

    Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

    Pimavanserin, Placebo

    Adjunctive Treatment of Major Depressive Disorder

    Enrollment
    298
    Start
    Apr 2019
    Primary Completion
    Apr 2020
    Completion
    May 2020
    NCT03968159
  • Phase 3
    Terminated

    Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

    Pimavanserin

    Adjunctive Treatment of Major Depressive Disorder

    Enrollment
    235
    Start
    Jun 2019
    Primary Completion
    Feb 2021
    Completion
    Feb 2021
    NCT04000009
  • Phase 3
    Completed

    Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

    Trofinetide

    Rett Syndrome

    Enrollment
    187
    Start
    Nov 2019
    Primary Completion
    Oct 2021
    Completion
    Oct 2021
    NCT04181723
  • Phase 3
    Completed

    Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

    Trofinetide

    Rett Syndrome

    Enrollment
    154
    Start
    Jan 2020
    Primary Completion
    Aug 2022
    Completion
    Aug 2022
    NCT04279314
  • Phase 3
    Completed

    Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

    Pimavanserin, Placebo

    Schizophrenia

    Enrollment
    454
    Start
    Aug 2020
    Primary Completion
    Jan 2024
    Completion
    Feb 2024
    NCT04531982
  • Phase 3
    Terminated

    Open-Label Extension Study of Trofinetide for Rett Syndrome

    trofinetide

    Rett Syndrome

    Enrollment
    77
    Start
    Nov 2020
    Primary Completion
    Jun 2023
    Completion
    Jun 2023
    NCT04776746
  • Phase 3
    Completed

    Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

    Carbetocin, Placebo

    Hyperphagia in Prader-Willi Syndrome

    Enrollment
    175
    Start
    Nov 2023
    Primary Completion
    Aug 2025
    Completion
    Aug 2025
    NCT06173531
  • Phase 3
    Enrolling by invitation

    ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

    ACP-204

    Alzheimer's Disease Psychosis

    Enrollment
    752
    Start
    Apr 2024
    Primary Completion
    Apr 2029est.
    Completion
    May 2029est.
    NCT06194799
  • Phase 3
    Terminated

    OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

    Carbetocin

    Hyperphagia in Prader-Willi Syndrome

    Enrollment
    168
    Start
    Mar 2024
    Primary Completion
    Dec 2025
    Completion
    Dec 2025
    NCT06420297
  • Phase 3
    Recruiting

    Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

    ACP-204

    Lewy Body Dementia Psychosis

    Enrollment
    126
    Start
    Nov 2025
    Primary Completion
    Feb 2029est.
    Completion
    Mar 2029est.
    NCT07095465
  • Phase 2/3
    Terminated

    An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome

    Trofinetide

    Rett Syndrome

    Enrollment
    15
    Start
    Sep 2021
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT04988867
  • Phase 2/3
    Completed

    Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder

    Pimavanserin, Placebo

    Irritability Associated With Autism Spectrum Disorder

    Enrollment
    237
    Start
    Aug 2022
    Primary Completion
    Sep 2024
    Completion
    Sep 2024
    NCT05523895
  • Phase 2/3
    Terminated

    Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

    Pimavanserin

    Irritability Associated With Autism Spectrum Disorder

    Enrollment
    209
    Start
    Nov 2022
    Primary Completion
    Feb 2025
    Completion
    Feb 2025
    NCT05555615
  • Phase 2/3
    Recruiting

    ACP-204 in Adults With Alzheimer's Disease Psychosis

    ACP-204, Placebo

    Alzheimer's Disease Psychosis

    Enrollment
    1,074
    Start
    Nov 2023
    Primary Completion
    Jan 2028est.
    Completion
    Feb 2028est.
    NCT06159673
  • Phase 2
    Completed

    Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

    ACP-103

    Hallucinations, Psychoses +1

    Enrollment
    60
    Start
    Mar 2004
    Primary Completion
    -
    Completion
    Dec 2005
    NCT00087542

1-25 of 41

Search ClinicalTrials.gov for “Acadia Pharmaceuticals”